Compare Sanofi SA (SNY) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Ishares Msci Thailand Etf — how do they compare? Sanofi SA trades at $43.99 (market cap $104.57B), while Ishares Msci Thailand Etf trades at $72.91. The key difference: Sanofi SA pays a 5.56% dividend while Ishares Msci Thailand Etf pays none, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | THD | |
|---|---|---|
Market Cap | $104.57B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $75.05 |
52-Week Low | $41.33 | $56.41 |
Enterprise Value | $124.48B | — |
Dividend Yield | 5.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
THD trades at $73.63, up 1.03% for the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock has shown strong performance, driven by exposure to AI hardware plays like Delta Electronics, contributing to its 38% total returns over the past year, as noted by Seeking Alpha on July 9, 2026. A dividend of $1.71 is scheduled for June 2026, adding income potential.
Outlook remains positive due to AI-driven growth, but risks include vulnerability to semiconductor sector volatility and foreign capital outflows from Asian equities. Investors should weigh the bullish technicals against macroeconomic uncertainties in the region for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
